GC America Inc.
$524.2K 2,479 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Astellas Pharma Europe Ltd
Astellas Pharma Europe Ltd reported $523,160.51 across General Payments, Research, and Ownership to 167 physicians and teaching hospitals across 167 transactions.
- $523.2K Above-median payer
- All-tracks total
- 167 Above-median volume
- Transactions
- 167 Above-median reach
- Recipients
- #750
- of 1,925 companies
Astellas Pharma Europe Ltd reported $523,160.51 across all CMS Open Payments tracks (General + Research + Ownership) to 167 physicians and teaching hospitals in Program Year 2024 - ranking #750 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $523,160.51, averaging $3.1K per recipient.
Astellas Pharma Europe Ltd's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
15/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer astellas-pharma-europe-ltd Astellas Pharma Europe Ltd
$523.2K · #750/1,925 · 0.0% industry · PY2024
- TOT $523.2K
- RANK #750
- SHARE 0.0%
- TXN 167
- RCP 167
- CAT 4
- GEN $523.2K
- TOP1 29.0%
- PY 2024
Volume peers
Nearest volume peer: GC America Inc. ($524.2K)
Astellas Pharma Europe Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Astellas Pharma Europe Ltd
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Astellas Pharma Europe Ltd that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Consulting Fee" leads the 4-category general-payment breakdown below at $287.7K (55.0% of General Payments, 47 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 4 types of general payments, Astellas Pharma Europe Ltd's largest category was "Consulting Fee" at $287.7K - 55.0% of General Payments.
Astellas Pharma Europe Ltd reports 4 general-payment categories - the top three are Consulting Fee (55.0%), Travel and Lodging (42.5%), and Compensation for Services Other Than Consulting (2.2%). The remaining 1 category make up 0.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Astellas Pharma Europe Ltd divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $287.7K | 47 | 55.0% |
| Travel and Lodging | $222.5K | 63 | 42.5% |
| Compensation for Services Other Than Consulting | $11.4K | 1 | 2.2% |
| Food and Beverage | $1.6K | 56 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $311,094.32 (59.5%) of $523,160.51 in this company's General Payments records across 19 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Astellas Pharma Europe Ltd
The five named recipients with the highest reported General Payments from this company
- 1
Stephen Freedland
$151,538.63 across 27 reported transactions
- 2
Terence Friedlander
$45,633.38 across 10 reported transactions
- 3
Peter O Donnell
$41,977.00 across 5 reported transactions
- 4
Steven Goldstein
$38,338.79 across 22 reported transactions
- 5
Vadim S Koshkin
$33,606.52 across 17 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Astellas Pharma Europe Ltd's spend rank (#750 of 1,925, top 39% by spend) and concentration rank (#928 of 1,838, top 50% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Whip Mix Corporation : $1.5K total payments, HHI 1295
- Daiichi Sankyo Company LTD : $316.4K total payments, HHI 1293
- Collagen Matrix, Inc : $83.9K total payments, HHI 1290
- Nvision Biomedical Technologies, Inc. : $80.7K total payments, HHI 1290
- IMPLANET America, Inc. : $12.6K total payments, HHI 1277
- Aero US Inc : $19.3K total payments, HHI 1269
- Astellas Pharma Europe Ltd (this company) : $523.2K total payments, HHI 1263
- Coltene Whaledent Inc. : $105.1K total payments, HHI 1261
- Mylan Inc. : $367.4K total payments, HHI 1254
- RGH Enterprises LLC : $7.4K total payments, HHI 1248
- Summit Surgical Corp. : $5.2K total payments, HHI 1241
- Vector Surgical, LLC : $29.7K total payments, HHI 1240
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Astellas Pharma Europe Ltd's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Astellas Pharma Europe Ltd.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Astellas Pharma Europe Ltd.
Showing 6 of 1,924 companies with CMS-reported payment data.
Genesis Software Innovations, LLC
$520.5K 8 recipients
Compare payment profiles
Veryan Medical Incorporated
$525.9K 278 recipients
Compare payment profiles
OraSure Technologies Inc.
$529.4K 45 recipients
Compare payment profiles
Painteq LLC
$516.0K 4,787 recipients
Compare payment profiles
Dynavax Technologies Corporation
$530.5K 5,747 recipients
Compare payment profiles
Put this to use
Astellas Pharma Europe Ltd ranks #750 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Astellas Pharma Europe Ltd. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.